Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 63 | ECE2019 | Next issue

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

Card image cap
18-21 May 2019, Lyon, France

Symposia

Innovations in NETs

ea0063s14.1 | Innovations in NETs | ECE2019

Innovative imaging of benign insulinomas – the end of sampling

Christ Emanuel

Background: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults and due to their small size difficult to localise. Until now, the most sensitive test to localize the area of the potential insulinoma was the intra-arterial calcium stimulation test, an invasive procedure with its associated risk. In contrast to the other neuroendocrine tumors, benign insulinomas do not exhibit upregulated somatostatin receptors sutype 2 (...

ea0063s14.2 | Innovations in NETs | ECE2019

A role for radionuclide therapy for high-grade NETs

Sorbye Halfdan

Background: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic low-grade and intermediate-grade neuroendocrine tumors (G1-G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3: NET G3 and NEC) has been unknown.Methods: Data from 3 recent retrospective studies (Thang et al. 2018, Zhang et al. 2018, Carlsen et al. 2019) on efficacy and to...

ea0063s14.3 | Innovations in NETs | ECE2019

Fishing for NETs

Vitale Giovanni

Neuroendocrine tumors (NETs) are a class of rare and heterogeneous neoplasms derived from the neuroendocrine system. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for NETs, probably due to the rarity and heterogeneity of this group of neoplasms. The tropical teleost zebrafish (Danio rerio) is a popular vertebrate mode...